The first attempt worldwide to test PD-1 antibody on multiple “Stage 0” lung cancer

The editorial board recently noticed that a Chinese research team had launched a phase II, prospective, Simon’s two-stage design study which evaluates the efficacy and safety of PD-1 antibody Sintilimab on unresectable early-stage multiple primary lung cancer (MPLC) with ground-glass density (CCTC-1901, NCT04026841) (Figure 1). This is the first documented study worldwide to test PD-1 antibody on “Stage 0” lung cancer, on July 24, 2019.